Atai Life Sciences is a clinical-stage biopharmaceutical company developing novel therapeutics for mental health conditions. They are advancing psychedelic and non-psychedelic compounds, including DMT, MDMA, and psilocin, to offer rapid-acting and durable relief for patients with treatment-resistant depression, social anxiety disorder, and cognitive impairment.

Beckley Psytech is developing a novel synthetic intranasal formulation of 5-MeO-DMT benzoate, designed to provide rapid and lasting treatment effects for mental health conditions such as Treatment Resistant Depression and Alcohol Use Disorder. The company addresses the significant unmet need for effective and accessible mental health treatments by leveraging next-generation psychedelic compounds that can be administered in a short clinic visit.

Cybin develops tryptamine-based psychedelic therapeutics using proprietary drug discovery platforms and controllable drug delivery systems to treat mental health conditions such as Major Depressive Disorder and Generalized Anxiety Disorder. The company aims to provide safe and effective treatment options that address the unmet needs of patients suffering from these disorders.

Delix Therapeutics develops neuroplastogens, a novel class of compounds that promote neuroplasticity to enhance brain health. Their approach targets neuropsychiatric conditions by repairing neural circuits and improving mental function through safe and fast-acting treatments.

Fauna Bio utilizes an AI-driven platform, Convergence™, to analyze genetic data from diverse mammalian species, enabling the discovery of novel therapeutic targets for age-related diseases and metabolic disorders. By replicating the natural disease resistance mechanisms found in these animals, the company aims to develop effective drugs that can improve human health outcomes.

Journey Clinical is a platform that partners with licensed mental health professionals to provide Ketamine-Assisted Psychotherapy (KAP), a treatment that combines off-label ketamine administration with specialized psychotherapy. This approach effectively addresses treatment-resistant depression and anxiety, with 87% of patients reporting improved clinical outcomes after just two visits.

Kadence Bio is a clinical-stage life sciences company developing novel therapeutics for sexual and mental health conditions. The company's lead asset, KH-001, is in development as the first FDA-approved treatment for premature ejaculation. Kadence Bio also maintains a pipeline of compounds targeting various mood disorders.

Ksana Health provides a clinical behavior change platform that utilizes mobile sensing technology to collect and analyze behavioral health data, enabling healthcare practitioners to deliver personalized interventions between appointments. This approach enhances patient engagement and adherence to evidence-based therapy, ultimately improving mental health outcomes.

The startup develops genome-based therapeutics utilizing fungal metabolites to address psychiatric and neurological disorders. By researching various fungal species, the company aims to enhance drug development for medical professionals, promoting the therapeutic potential of fungi for human health.

Pangea Bio is a clinical-stage biotech company focused on developing transformative medicines for neurological and mental health disorders. The company's core research targets the TrkB receptor pathway to promote neuronal survival and synaptic plasticity. Their lead candidate, OT-003, and subsequent pipeline assets are designed to address significant unmet needs in CNS diseases.

The startup develops targeted pharmacological therapies for treating substance use disorders, utilizing evidence-based approaches to enhance patient adherence and recovery outcomes. By addressing the barriers to effective treatment, the company enables individuals struggling with addiction to achieve sustainable recovery and improved quality of life.

Transcend Therapeutics develops novel, rapid-acting treatments targeting neuropsychiatric diseases for patients underserved by current medications. The company's pipeline focuses on compounds like TSND-201, a neuroplastogen being investigated for severe Post-Traumatic Stress Disorder (PTSD). They aim to deliver robust and long-lasting therapeutic options through advanced pharmacological approaches.

Xylo AI provides a real-time client intelligence platform for Registered Investment Advisors (RIAs) by transforming natural client communications into actionable insights. The platform integrates CRM data, emails, and calls to generate behavioral insights, risk signals, and opportunity alerts. This enables advisors to build and execute prioritized task lists automatically, improving client retention and engagement efficiency.